p53 abnormalities are regarded as an independent prognostic marker in multiple myeloma. Patients harbouring this genetic anomaly are commonly resistant to standard therapy. Thus, various p53 reactivating agents have been developed in order to restore its tumour suppressive abilities. Small molecular compounds, especially, have gained popularity in its efficacy against myeloma cells. For instance, promising preclinical results have steered both nutlin-3 and PRIMA-1 into phase I/II clinical trials. This review summarizes different modes of p53 inactivation in myeloma and highlights the current p53-based therapies that are being utilized in the clinic. Finally, we discuss the potential and promise that the novel small molecules possess for clinical application in improving the treatment outcome of myeloma. © 2014 P. J. Teoh and W. J. Chng.
Teoh, P. J., & Chng, W. J. (2014). P53 abnormalities and potential therapeutic targeting in multiple myeloma. BioMed Research International. Hindawi Publishing Corporation. https://doi.org/10.1155/2014/717919